EV is an antibody-drug conjugate with monoclonal antibody directed against nectin-4, expressed on urothelial cells, conjugated to the microtubule disruptor monomethyl auristatin E (MMAE) used in the treatment of advanced urothelial carcinoma.1 The gene discussed is NECTIN4; the disease is urothelial carcinoma.